Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Epothilones

Criteria

Inclusion Criteria:

• Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV.

• Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC.

• Good performance status.

Exclusion Criteria:

• Prior treatment with an epothilone.

• Known central nervous system (CNS) metastases.

• Any chemotherapy, radiation therapy or immunotherapy or any investigational agent (therapeutic or diagnostic) within 3 weeks prior to first study drug administration.